<DOC>
	<DOC>NCT03065309</DOC>
	<brief_summary>This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension</brief_summary>
	<brief_title>Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults</brief_title>
	<detailed_description>Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life. Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Bradycardia</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<criteria>Indication of anesthesia induction Protocol violation Monitoring problems</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>